Role of the oral beta-lactams in the treatment of exacerbations of chronic bronchitis: Critical analysis and therapeutic recommendations

Journal of Chemotherapy

Volumn 22, Issue , 2010, Pages 3-28

  Blasi, F ^a   Concia, E ^b   Mazzei, T ^c   Moretti, A M ^d   Nicoletti, G ^e   Novelli, Andrea ^c   Tempera, G ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b GB Rossi Polyclinic Borgo Roma ^*  (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d GENERAL HOSPITAL   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

Author keywords

ABECB; Amoxicillin clavulanate; Beta lactams; Cefditoren; Chronic obstructive pulmonary disease (COPD)

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFALEXIN; CEFDITOREN; CEFDITOREN PIVOXIL; CEFIXIME; CEFPODOXIME; CEFPROZIL; CEFTIBUTEN; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; PRULIFLOXACIN; QUINOLONE DERIVATIVE; TETRACYCLINE; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBIOTIC RESISTANCE; ARTICLE; CHRONIC BRONCHITIS; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; HAEMOPHILUS INFLUENZAE; HUMAN; ITALY; LUNG EMPHYSEMA; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; SENTINEL SURVEILLANCE; SMOKING; STREPTOCOCCUS PNEUMONIAE; THERAPEUTIC INDEX; TIME TO MAXIMUM PLASMA CONCENTRATION; BACTERIAL INFECTION; BACTERIUM; MICROBIOLOGY; PATHOGENICITY; PRACTICE GUIDELINE; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; ACUTE RESPIRATORY TRACT DISEASE; ANTIBIOTIC THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BETA-LACTAMS; BRONCHITIS, CHRONIC; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79958008806     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.Supplement-1.3     Document Type: Article

References (127)

1. Celli BR, Macnee W; ATs/ERs Task Force. standards for the diagnosis and treatment of patients with COPD: a summary of the ATs/ERs position paper. Eur Respir J 2004;23(6):932-946.
2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist sA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532-555.
3. Global strategy for the Diagnosis, Management and Prevention of COPD, Global initiative for Chronic Obstructive Lung Disease (GOLD) 2008.
4. European Respiratory society, European Lung Foundation. European Lung White Book, 2003: 34-43.
5. Viegi G, Pistelli F, sherrill DL, Maio S, Baldacci S, Carrozzi L. Definition, epidemiology and natural history of COPD. Eur Respir J 2007;30(5):993-1013.
6. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, nizankowska-Mogilnicka E; BOLD Collaborative Research Group. international variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet 2007;370(9589):741-750.
7. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(suppl 2):398s-401s.
8. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003;41(suppl):46s-53s.
9. O’Donnell DE, Aaron S, Bourbeau J, Hernandez P et al. Canadian Thoracic society recommendations for management of chronic obstructive pulmonary disease. 2007 Update.Can Respir J 2007;14 (suppl B):5B-32B.
10. seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-1613.
11. Burrows B, Earle RH. Course and prognosis of chronic obstructive lung disease.A prospective study of 100 patients. n Engl J Med 1969;280:397-404
12. seemungal TA, Donaldson GC, Paul EA, Bestall JC et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422.
13. niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med 2006;119(suppl1):38-45.
14. Kanner RE, Anthonisen nR, Connett JE, Lung Health study Research Group. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: Results from the Lung Health study. Am J Respir Crit Care Med 2001;164:358-364.
15. Wilkinson TM, Donaldson GC, Hurst JR, seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:1298-1303.
16. Kong GK, Belman MJ, Weingarten S. Reducing length of stay for patients hospitalized with exacerbation of COPD by using a practice guideline. Chest 1997;111:89-94.
17. Gunen H, Hacievliyagil SS, Kosar F, Mutlu LC, Gulbas G, Pehlivan E, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J 2005;26:234-241.
18. Fuso L, incalzi RA, Pistelli R, Muzzolon R, Valente S, Pagliari G, et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995;98(3):272-277.
19. Burk RH, George RB. Acute respiratory failure in chronic obstructive pulmonary disease. immediate and long-term prognosis. Arch intern Med 1973;132:865-868.
20. Portier F, Defouilloy C, Muir JF. Determinants of immediate survival among chronic respiratory insufficiency patients admitted to an intensive care unit for acute respiratory failure. A prospective multicenter study. The French Task Group for Acute Respiratory Failure in Chronic Respiratory insufficiency. Chest 1992;101:204-210.
21. seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and one-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995;274:1852-1857.
22. Cao Z, Ong KC, Eng P, Tan WC, Ng TP. Frequent hospital readmissions for acute exacerbation of COPD and their associated factors. Respirology 2006;11:188-195.
23. Osman IM, Godden DJ, Friend JA, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997;52:67-71.
24. Hurst JR, Donaldson GC, Quint JK, Goldring JJP, Baghai-Ravary R, Wedzicha JA. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;179:369-374.
25. White AJ, Gompertz S, stockley RA. Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003;58:73-80.
26. Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJ, Murphy TF. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000;118:1557-1565.
27. White AJ, Gompertz S, Bayley DL, Hill SL, O’Brien C, Unsal I, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003;58:680-685.
28. Dal negro R, Rossi A, Cerveri I. The burden of COPD in italy: results from the confronting COPD survey. Respir Med 2003;97 (suppl C):s43-s50.
29. Detournay B, Pribil C, Fournier M and the sCOPE Group. The sCOPE study: health care consumption related to patients with chronic obstructive pulmonary disease in France. Value Health 2004;7:168-174.
30. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000;118:1278-1285.
31. Lucioni C, Donner CF, De Benedetto F, Lusuardi M, Mazzi S, Paggiaro PL, et al. i costi della broncopneumopatia cronica ostruttiva: la fase prospettica dello studio iCE (Italian Costs for Exacerbations in COPD). Pharmacoeconomics-italian Research Articles 2005;7:119-134.
32. skwarska E, Cohen G, skwarski KM, Lamb C, Bushell D, Parker S, et al. Randomised controlled trial of supported discharge in patients with exacerbations of chronic obstructive pulmonary disease. Thorax 2000;55:907-912.
33. Davies L, Wilkinson M, Bonner S, Calverley PM, Angus RM. “Hospital at home” versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease: prospective randomised controlled trial. Br Med J 2000;321:1265-1268.
34. Ojoo JC, Moon T, McGlone S, Martin K, Gardiner ED, Greenstone MA, et al. Patients’ and carers’ preferences in two models of care for acute exacerbations of COPD: results of a randomised controlled trial. Thorax 2002;57:167-169.
35. Hernandez C, Casas A, Escarrabill J, Alonso J, Puig-Junoy J, Farrero E, et al. Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. Eur Respir J 2003;21: 58-67.
36. Sethi S. infectious etiology of acute excerbations of chronic bronchitis. Chest 2000; 117 (5 suppl 2):380-385
37. Ott SR, Rohde G, Lepper PM, Hauptmeier B, Bals R, Pletz MW et al. The impact of viruses in lower respiratory tract infections of the adult. Part ii: acute bronchitis. acute exacerbated COPD pneumonia and influenza. Pneumologie 2010;64(1):18-27.
38. Sethi S. infectious exacerbations of chronic bronchitis: diagnosis and management. J Antimicrob Chemother 1999;43(suppl A):97-105
39. Blasi F, Tarsia P, Aliberti S. Chlamydophila pneumoniae. Clin Microbiol infect. 2009;15(1):29-35. Review.
40. Diekema DJ, Brueggemann AB, Doern GV. Antimicrobialdrug use and changes in resistance in Streptococcus pneumoniae. Emerg infect Dis 2000;6(5):552-556.
41. Cizman M, Pokorn M, seme K, Orazem A, Paragi M. The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. J Antimicrob Chemother 2001;47(4):475-477.
42. García-Rey C, Aguilar L, Baquero F, Casal J, Dal-Ré R. importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol 2002;40 (1):159-164.
43. Alpuche C, Garau J, Lim V. Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens. int J Antimicrob Agents 2007;30(suppl 2):135-138.
44. Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev 2007;20(2):368-389.
45. Verduin CM, Hol C, Fleer A, van Dijk H, van Belkum A. Moraxella catarrhalis: from emerging to established pathogen. Clin Microbiol Rev 2002;15(1):125-144.
46. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy 2004;50(suppl 1):3-10.
47. REPORT EARss 2008 EARss Management Team. Annual Report 2008. October 2009; national institute for Public Health and Environment. Bilthoven. The netherlands http://www.rivm.nl/earss/images/EARss%202008_final_tcm6 1-65020.pdf
48. Blasi F, Farrell DJ, Dubreuil L. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the prospective resistant organism tracking and epidemiology for the ketolide telithromycin. Diagn Microbiol infect Dis 2009;63:302-308.
49. Cocuzza CE, Viganò EF, Bramati S, Fornara AM, Lanzafame S. studio sull’antibiotico-resistenza delle Pneumococco. Microbiologia Medica 1994;9:21-21.
50. schito GC, Debbia E, Chezzi C, Crotti D, Fortina G, et al. Antibiotico-resistenza di ceppi clinici di Streptococcus pneumoniae isolati in italia. Microbiologia Medica 1994;9:532-534.
51. Montagnani F, stolzuoli L, Zanchi A, Cresti S, Cellesi C. Antimicrobial susceptibility of Streptococcus pyogenes and Streptococcus pneumoniae: surveillance from 1993 to 2004 in Central italy. J Chemother 2006;18(4):389-393.
52. Marchese A, Debbia EA, Arvigo A, Pesce A, schito GC. susceptibility of Streptococcus pneumoniae strains isolated in italy to penicillin and ten other antibiotics. J Antimicrob Chemother 1995;36:833-837.
53. Felmingham D, Grüneberg RN. A multicentre collaborative study of the antimicrobial susceptibility of community-acquired. lower respiratory tract pathogens 1992-1993: the Alexander Project. J Antimicrob Chemother 1996;38(suppl A):1-57.
54. schito GC., Mannelli S., Pesce A. Trends in the activity of macrolide and beta-lactam antibiotics and resistance development. Alexander Project Group. J Chemother 1997;9(suppl 3):18-28.
55. schito GC, Mannelli S, Cibraio-Sent M, Pesce A, Marchese A. Osservatorio Epidemiologico italiano. Patogeni batterici respiratori comunitari e nosocomiali: analisi delle resistenze nel 1997: Streptococcus pneumoniae. GiMMOC 1999; 3(1):11-24.
56. schito GC, Mannelli S, Cibraio-sent M, Pesce A, Marchese A. Evoluzione delle resistenze ai farmaci antimicrobici in Streptococcus pneumoniae circolante in italia. Analisi dei dati dell’Osservatorio Epidemiologico italiano (1998). GiMMOC 1999;3(1):43-57.
57. schito GC, Mannelli S, Cibraio-sent M, Pesce A, Marchese A. Resistenza ai farmaci antimicrobici in Streptococcus pneumoniae circolanti nel 1999 in italia. GiMMOC 2000;4(1):13-30.
58. Marchese A, Ardito F, Fadda G, Fontana R, Lo Cascio G, et al. The sentinel Project: an update on the prevalence of antimicrobial resistance in community-acquired respiratory Streptococcus pneumoniae and Haemophilus spp. in italy. int J Antimicrob Agents 2005;26(1):8-12.
59. Deshpande LM, sader HS, Debbia E, nicoletti G, Fadda G, Jones RN, et al. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from italy: report from the sEnTRY Antimicrobial surveillance Program (2001-2004). Diagn Microbiol infect Dis 2006;54(3):157-164.
60. Boccia D, Alegiani SS, Pantosti A, Moro ML, Traversa G. The geographic relationship between the use of antimicrobial drugs and the pattern of resistance for Streptococcus pneumo-niae in italy. Eur J Clin Pharmacol 2004;60(2):115-119.
61. Petrosillo N, Pantosti A, Bordi E, spanó A, Del Grosso M, Tallarida B, et al. Prevalence determinants. and molecular epidemiology of Streptococcus pneumoniae isolates colonizing the nasopharynx of healthy children in Rome. Eur J Clin Microbiol infect Dis 2002;21(3):181-188.
62. Clinical and Laboratory standards institute. Performance standards for antimicrobial susceptibility testing. 2008; 18th informational supplement. M100-s18. CLsi. Wayne. PA.
63. Gherardi G, D’Ambrosio F, Monaco M, Camilli R, De Florio L, D’Ancona F, et al. Population structure of invasive Streptococcus pneumoniae isolates in italy prior to the implementation of the 7-valent conjugate vaccine (1999-2003). Eur J Clin Microbiol infect Dis 2009;28(1):99-103.
64. stefani S, Mezzatesta ML, Fadda G, Mattina R, Palù G, Rossano F, et al. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in italy. J Chemother 2008;20(5):561-569.
65. Tempera G, Furneri PM, Carlone N, Cocuzza C, Rigoli R, Musumeci R, et al. Antibiotic susceptibility of respiratory pathogens recently isolated in italy: focus on cefditoren. J Chemother 2010;22(3), 153-159.
66. Mazzei T, novelli A. Cefditoren pivoxil: Una nuova cefalosporina orale per il trattamento delle infezioni respiratorie comunitarie. Farmaci & Terapia 2008;xxV:1-20.
67. Jones RN, Biedenbach DJ, Croco MA, Barrett MS. In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Diagn Microbiol infect Dis 1998;31:573−578.
68. Jones RN, Pfaller MA, Jacobs MR, Appelbaum PC, Fuchs PC. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Diagn Microbiol infect Dis 2001;41:1−14.
69. Clark CL, nagai K, Dewasse BE, Pankuch GA, Ednie LM, Jacobs MR et al. Activity of cefditoren against respiratory pathogens. J Antimicrob Chemother 2002;50:33−41.
70. Biedenbach DJ, Jones RN. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures. including recent pharmacodynamic considerations. Diagn Microbiol infect Dis 2009;64:202-212.
71. Mazzei T, novelli A, Mini E, Periti P. Penicilline, Cefalosporine ed altre -lattamine. in in: Trattato di Farmacologia. A cura di F. Rossi, C. Riccardi, V. Cuomo, 2005.
72. Petri WA Jr. Charter 44-Penicillins, cephalosporins, and other -lactam antibiotics. in Goodman & Gilman’s (eds): The pharmacological basis of therapeutics. Eleventh Edition. Mc-Graw-Hill, 2006;1127-1154.
73. Mazzei T, Novelli A. Cefditoren pivoxil. Una nuova cefalosporina orale per il trattamento delle infezioni respiratorie co munitarie. “Rassegna della letteratura internazionale”. Farmaci & Terapia 2008; 25(1-2): 1-20.
74. Periti P, Mazzei T, Mini E, novelli A, Reali EF. Attualità delle cefalosporine in chemioterapia. Edizioni Riviste scientifiche, Firenze, 1988.
75. Fallani S, Cassetta MI, Arrigucci S, Novelli A. Aspetti farmacologici delle cefalosporine. Farmaci & Terapia 2003; 20(1-2): 9-18.
76. Novelli A, Fallani S, Cassetta MI, Conti S. Pharmacokinetics and pharmacodynamics of oral cephalosporins as critical factors in choice of antibiotics. int J Antimicrob Agents 2000; 501-505.
77. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin infect Dis 1998; 26:1-10.
78. Craig WA. interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broadspectrum cephalosporins. Diagn Microbiol infect Dis 1995; 22: 89-96.
79. MacGowan AP, Bowker KE. Pharmacodynamics of antimicrobial agents and rationale for their dosing. Chemotherapy 1997; 9(suppl 1): 64-73.
80. Craig WA, Gudmundsson S. Postantibiotic effect. in : Lorian V (ed). Antibiotics in Laboratory Medicine. Third Edition. Williams & Wilkins, 1991: 403.
81. Craig WA. Post-antibiotic effects in experimental infection models; relationship to in vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 1993; 31(suppl D): 149-158.
82. Felmingham D, Robbins MJ, Ghosh G, Bhogal H, Mehta MD, Leakey A, e coll. An in vitro characterization of cefditoren, a new oral cephalosporin. Drugs Exp Clin Res 1994; 20: 127-147.
83. Dubois J, st-Pierre C. In vitro study of the post-antibiotic effect and the bactericidal activity of cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens. Diagn Microbiol infect Dis 2000; 37: 187-193.
84. White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. Augmentin® (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004; 53(suppl s1): i3-i20.
85. nix DE, Goodwin SD, Peloquin CA, Rotella DL, schentag JJ. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother 1991; 35: 1947-1952.
86. nix DE, Goodwin SD, Peloquin CA, Rotella DL, schentag JJ. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother. 1991; 35: 1953-1959.
87. Cook PJ, Andrews JM, Woodcock J, Wise R, Honeybourne D. Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection. Thorax 1994; 49(11): 1134-1138.
88. Gould IM, Harvey G, Golder D, Reid TM, Watt SJ, Friend JA, Legge JS, Douglas JG. Penetration of amoxycillin/clavulanic acid into bronchial mucosa with different dosing regimens. Thorax 1994; 49(10): 999-1001.
89. Kinzig-schippers M, Hinder M, Gohler K, et al. Tissue penetration of cefditoren (CEE) into bronchial mucosa (BM) and epithelial lining fluid (ELF) in patients undergoing fiberoptic bronchoscopy [abstract no. 946]. 41st interscience Conference on Antimicrobials Agents and Chemotherapy; 2001 Dec 16-19; Chicago, 24
90. stefani S, Mezzatesta ML, Fadda G, Mattina R, Palù G, Rossano F, et al. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in italy. J Chemother 2008; 20(5): 561-569.
91. Tempera G, Furneri PM, Carlone NA, Cocuzza C, Riboli R, Musumeci R, et al. Epidemiology of Respiratory Pathogens isolated in italy in 2009: Focus on Cefditoren. J Chemother 2010 in press.
92. sánchez navarro A. new formulations of amoxicillin/ clavulanic acid: a pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 2005; 44(11): 1097-1115.
93. Scaglione F, schito GC, Principi N, Bettoncelli G. Ruolo di cefpodoxime proxetil tra le cefalosporine orali nella moderna antibioticoterapia delle infezioni respiratorie comunitarie. GiMMOC 2005; 9(1): 39-52.
94. Owens RC Jr, nightingale CH, nicolau DP. Ceftibuten: an overview. Pharmacotherapy 1997; 17(4): 707-720.
95. Morrissey I, Colclough A, northwood J. TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community-acquired respiratory tract infections in 2003 to fluoroquinolones and other agents. int J Antimicrob Agents 2007; 30(4): 345-351.
96. Fenoll A, Giménez MJ, Robledo O, Aguilar L, Tarragó D, Granizo JJ, et al. influence of penicillin/amoxicillin non-susceptibility on the activity of third-generation cephalosporins against Streptococcus pneumoniae. Eur J Clin Microbiol infect Dis 2008; 27: 75-80.
97. sádaba B, Azanza JR, Quetglas EG, Campanero MA, Honorato J, Coronel P, et al. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice-and thrice-daily regimens in healthy volunteers: a phase i study. Rev Esp Quimioter 2007; 20(1): 51-60.
98. nicolau DP, Quintiliani R. Choosing between the new cephalosporin antibiotics. A pharmacological approach. PharmacoEconomics 1994; 5(suppl 2): 34-39.
99. novelli A, Cassetta MI, Mini E, Mazzei T. Fluorochinoloni. in “Farmacologia, principi di base ed applicazioni terapeutiche” Rossi F, Cuomo V and RiccardiC Eds, Minerva Medica, Turin 2005: 600-610.
100. Domagala J. M. structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994; 33(4): 685-706.
101. Forrest A, nix DE, Ballow CH, Goss TF, Birmingham MC, schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993; 37: 1073-1081.
102. schentag JJ, strenkoski-nix LC, nix DE, Forrest A. Pharmacodynamic interactions of antibiotics alone and in combination. Clin infect Dis 1998;27:40-46.
103. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125-129.
104. Pickerill KE, Paladino JA, schentag JJ. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy 2000; 20: 417-428.
105. Jumbe nL, Louie A, Liu W, Deziel M, Miller MH, Drusano GL. Pharmacodynamics of levofloxacin with different organisms: one size does not fit all. 40th iCAAC, Toronto, Canada, sept. 17-20 2000, Abst. 292.
106. schentag JJ. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae. J Chemother 2002; 14(suppl 2): 13-21.
107. nightingale CH, Grant EM, Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy 2000; 46(suppl 1): 6-14.
108. Firsov AA, Zinner SH, Vostrov SN, Portnoy YA, Lubenko IY. AUC/MiC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J Antimicrob Chemother 2002; 50(4): 533-539.
109. Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician 2002; 65: 455-464.
110. novelli A, Mini E, Mazzei T. Pharmacological interactions between antibiotics and other drugs in the treatment of lower respiratory tract infections. Eur Respir Mon 2004; 9(28): 229-254.
111. Mazzei T, novelli A. Valutazione farmacodinamico-far macocinetica dei macrolidi glucosidici. Farmaci & Terapia 2006; 23(1-2): 3-13.
112. Bryskier A, Labro MT. Macrolides. new therapeutic prospects. Presse Med 1994; 23(38): 1762-1766.
113. novelli A, Fallani S, Cassetta MI, Arrigucci S, Mazzei T. in vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin. J Chemother 2002; 14: 584-590.
114. Periti P, Mazzei T, Mini E, novelli A. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part i). Clin Pharmacokinet 1989; 16: 193-214.
115. Periti P, Mazzei T, Mini E, novelli A. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part ii). Clin Pharmacokinet 1989; 16: 261-282.
116. Rubinstein E. Comparative safety of the different macrolides. int J Antimicrob Agents 2001; 18(suppl 1): s71-s76.
117. Periti P, Mazzei T, Mini E, novelli A. Adverse effects of macrolide antibacterials. Drug saf 1993; 9: 346-364.
118. Burley CJ, Masterton RG, Lovell DP. indicators of bacterial infection in patients with acute exacerbation of chronic bronchitis for application in clinical trials of antibacterial drugs. J infect. 2007; 55(3):226-32.
119. Higgins K, singer M, Valappil T, nambiar S, Lin D, Cox E. Overview of recent studies of community-acquired pneumonia. Clin infect Dis. 2008; 47 suppl 3:s150-6.
120. Dal negro RW, Berto P, Tognella S, Quareni L. Cost of illness of lung disease in the Triveneto Region, italy: the GOLD study. Monaldi Arch Chest Dis 2002; 57: 1, 3-9.
121. Ministero della salute dati del 2002.
122. Sethi S. Pathogenesis and treatment of acute exacerbations of chronic obstructive pulmonary disease. semin Respir Crit Care Med. 2005; 26(2):192-203.
123. Dal negro RW, Micheletto C, Tognella S, Visconti M, Guerriero M, sandri MF. A two-stage logistic model based on the measurement of pro-inflammatory cytokines in bronchial secretions for assessing bacterial, viral, and non-infectious origin of COPD exacerbations. COPD. 2005;2(1):7-16.
124. Morris S, Anderson P, irwin DE. Acute exacerbations of chronic bronchitis: a pharmacoeconomic review of antibacterial use. Pharmacoeconomics. 2002;20(3):153-68.
125. Monte SV, Paolini NM, slazak EM, schentag JJ, Paladino JA. Costs of treating lower respiratory tract infections. Am J Manag Care. 2008;14(4):190-6.
126. Miravitlles M, Murio C, Guerrero T, Gisbert R; DAFnE study Group. Decisiones sobre Antibioticoterapia y Farmacoeconomía en la EPOC. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002;121(5):1449-55.
127. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive pulmonary disease: the sUPPORT investigators (study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154:959-967.